CoChat
Sign Up
Cited by 8

The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.

Neuroglia in neurodegeneration: Alzheimer, Parkinson, and Huntington disease

Lim, Dmitry, Matute, Carlos, Cavaliere, Fabio, Verkhratsky, Alexei·2025·Handbook of Clinical Neurology
DOI 10.1016/b978-0-443-19102-2.00012-0
Open this paper in CoChat — free account

Abstract

The conspicuous rise of chronic neurodegenerative diseases, including Alzheimer (AD), Parkinson (PD), and Huntington (HD) diseases, is currently without disease-modifying therapies and accompanied by an excessive rate of unsuccessful clinical trials. This reflects a profound lack of understanding of the pathogenesis of these diseases, indicating that the current paradigms guiding disease modeling and drug development are in need of reconsideration. The role of neuroglia, namely astrocytes, microglial cells, and oligodendrocytes, in the pathogenesis of neurodegenerative diseases emerged during the last decades. This chapter provides the state-of-the-art update on the changes of astrocytes, microglial cells, and oligodendrocytes in AD, PD, and HD. A growing body of evidence suggests that homeostatic and defensive functions of glial cells are compromised at different disease stages, leading to increased susceptibility of neurons to noxious stimuli, eventually resulting in their malfunction and degeneration. Investments are needed in the generation of novel preclinical models suitable for studying glial pathology, in "humanizing" research, and in-depth investigation of glial cell alterations to slow down and, possibly, halt and prevent the rise of neurodegenerative disease. Targeting glial cells opens new therapeutic avenues to treat AD, PD, and HD.

Overview

Integrity signals

Registry

Crossref · 10.1016/b978-0-443-19102-2.00012-0

Cites

63 of 63 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 331

  1. Abdelhak, 2022, Blood GFAP as an emerging biomarker in brain and spinal cord disorders, Nat Rev Neurol, 18, 158, 10.1038/s41582-021-00616-3 · DOI · Paper page
  2. Abdul, 2008, Oxidative damage in brain from human mutant APP/PS-1 double knock-in mice as a function of age, Free Radic Biol Med, 45, 1420, 10.1016/j.freeradbiomed.2008.08.012 · DOI
  3. Åbjørsbråten, 2022, Impaired astrocytic Ca2+ signaling in awake-behaving Alzheimer's disease transgenic mice, eLife, 11, 10.7554/eLife.75055 · DOI
  4. Alberch, 2002, Neuroprotection by neurotrophins and GDNF family members in the excitotoxic model of Huntington's disease, Brain Res Bull, 57, 817, 10.1016/S0361-9230(01)00775-4 · DOI
  5. Alberdi, 2013, Ca2+-dependent endoplasmic reticulum stress correlates with astrogliosis in oligomeric amyloid β-treated astrocytes and in a model of Alzheimer's disease, Aging Cell, 12, 292, 10.1111/acel.12054 · DOI
  6. Albini, 2023, Astrocytes and brain-derived neurotrophic factor (BDNF), Neurosci Res, 10.1016/j.neures.2023.02.001 · DOI
  7. Allen, 2002, Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein, J Neurosci, 22, 9340, 10.1523/JNEUROSCI.22-21-09340.2002 · DOI
  8. Andersen, 2022, Astrocyte energy and neurotransmitter metabolism in Alzheimer's disease: integration of the glutamate/GABA-glutamine cycle, Prog Neurobiol, 217, 10.1016/j.pneurobio.2022.102331 · DOI
  9. Anderson, 2017, Why do so many clinical trials of therapies for Alzheimer's disease fail?, Lancet, 390, 2327, 10.1016/S0140-6736(17)32399-1 · DOI · Paper page
  10. Andorfer, 2003, Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms, J Neurochem, 86, 582, 10.1046/j.1471-4159.2003.01879.x · DOI · Paper page
  11. André, 2010, Dopamine and glutamate in Huntington's disease: a balancing act, CNS Neurosci Ther, 16, 163, 10.1111/j.1755-5949.2010.00134.x · DOI
  12. Aoki, 2009, Role of nuclear transcription factor kappa B (NF-kappaB) for MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahyropyridine)-induced apoptosis in nigral neurons of mice, Exp Mol Pathol, 86, 57, 10.1016/j.yexmp.2008.10.004 · DOI
  13. Arnst, 2021, Deficiency in MT5-MMP supports branching of human iPSCs-derived neurons and reduces expression of GLAST/S100 in iPSCs-derived astrocytes, Cells, 10, 1705, 10.3390/cells10071705 · DOI
  14. Arregui, 2011, Adenoviral astrocyte-specific expression of BDNF in the striata of mice transgenic for Huntington's disease delays the onset of the motor phenotype, Cell Mol Neurobiol, 31, 1229, 10.1007/s10571-011-9725-y · DOI
  15. Bader Lange, 2010, Age-related loss of phospholipid asymmetry in APP(NLh)/APP(NLh) x PS-1(P264L)/PS-1(P264L) human double mutant knock-in mice: relevance to Alzheimer disease, Neurobiol Dis, 38, 104, 10.1016/j.nbd.2010.01.004 · DOI
  16. Baglietto-Vargas, 2021, Generation of a humanized Aβ expressing mouse demonstrating aspects of Alzheimer's disease-like pathology, Nat Commun, 12, 2421, 10.1038/s41467-021-22624-z · DOI
  17. Banerjee, 2022, Animal models in the study of Alzheimer's disease and Parkinson's disease: a historical perspective, Animal Model Exp Med, 5, 27, 10.1002/ame2.12209 · DOI
  18. Barak, 2022, Human iPSC-derived neural models for studying Alzheimer's disease: from neural stem cells to cerebral organoids, Stem Cell Rev Rep, 18, 792, 10.1007/s12015-021-10254-3 · DOI
  19. Barbar, 2020, CD49f is a novel marker of functional and reactive human iPSC-derived astrocytes, Neuron, 107, 436, 10.1016/j.neuron.2020.05.014 · DOI
  20. Bartels, 2010, [11C]-PK11195 PET: quantification of neuroinflammation and a monitor of anti-inflammatory treatment in Parkinson's disease?, Parkinsonism Relat Disord, 16, 57, 10.1016/j.parkreldis.2009.05.005 · DOI
  21. Bartzokis, 2011, Alzheimer's disease as homeostatic responses to age-related myelin breakdown, Neurobiol Aging, 32, 1341, 10.1016/j.neurobiolaging.2009.08.007 · DOI · Paper page
  22. Bartzokis, 2003, White matter structural integrity in healthy aging adults and patients with Alzheimer disease: a magnetic resonance imaging study, Arch Neurol, 60, 393, 10.1001/archneur.60.3.393 · DOI
  23. Bartzokis, 2010, Lifespan trajectory of myelin integrity and maximum motor speed, Neurobiol Aging, 31, 1554, 10.1016/j.neurobiolaging.2008.08.015 · DOI
  24. Bates, 2015, Huntington disease, Nat Rev Dis Primers, 1, 15005, 10.1038/nrdp.2015.5 · DOI · Paper page
  25. Bayram-Weston, 2012, Light and electron microscopic characterization of the evolution of cellular pathology in YAC128 Huntington's disease transgenic mice, Brain Res Bull, 88, 137, 10.1016/j.brainresbull.2011.05.005 · DOI
  26. Beauquis, 2013, Environmental enrichment prevents astroglial pathological changes in the hippocampus of APP transgenic mice, model of Alzheimer's disease, Exp Neurol, 239, 28, 10.1016/j.expneurol.2012.09.009 · DOI · Paper page
  27. Bechler, 2015, CNS myelin sheath lengths are an intrinsic property of oligodendrocytes, Curr Biol, 25, 2411, 10.1016/j.cub.2015.07.056 · DOI
  28. Ben Haim, 2015, The JAK/STAT3 pathway is a common inducer of astrocyte reactivity in Alzheimer's and Huntington's diseases, J Neurosci, 35, 2817, 10.1523/JNEUROSCI.3516-14.2015 · DOI · Paper page
  29. Benitez, 2014, White matter tract integrity metrics reflect the vulnerability of late-myelinating tracts in Alzheimer's disease, Neuroimage Clin, 4, 64, 10.1016/j.nicl.2013.11.001 · DOI
  30. Benraiss, 2021, Cell-intrinsic glial pathology is conserved across human and murine models of Huntington's disease, Cell Rep, 36, 10.1016/j.celrep.2021.109308 · DOI
  31. Bergami, 2008, Uptake and recycling of pro-BDNF for transmitter-induced secretion by cortical astrocytes, J Cell Biol, 183, 213, 10.1083/jcb.200806137 · DOI
  32. Berridge, 2010, Calcium hypothesis of Alzheimer's disease, Pflugers Arch, 459, 441, 10.1007/s00424-009-0736-1 · DOI
  33. Bido, 2021, Microglia-specific overexpression of α-synuclein leads to severe dopaminergic neurodegeneration by phagocytic exhaustion and oxidative toxicity, Nat Commun, 12, 6237, 10.1038/s41467-021-26519-x · DOI · Paper page
  34. Blanchard, 2003, Time sequence of maturation of dystrophic neurites associated with Abeta deposits in APP/PS1 transgenic mice, Exp Neurol, 184, 247, 10.1016/S0014-4886(03)00252-8 · DOI · Paper page
  35. Blesa, 2022, Motor and non-motor circuit disturbances in early Parkinson disease: which happens first?, Nat Rev Neurosci, 23, 115, 10.1038/s41583-021-00542-9 · DOI · Paper page
  36. Bolmont, 2007, Induction of tau pathology by intracerebral infusion of amyloid-beta -containing brain extract and by amyloid-beta deposition in APP x Tau transgenic mice, Am J Pathol, 171, 2012, 10.2353/ajpath.2007.070403 · DOI · Paper page
  37. Booth, 2017, The role of astrocyte dysfunction in Parkinson's disease pathogenesis, Trends Neurosci, 40, 358, 10.1016/j.tins.2017.04.001 · DOI · Paper page
  38. Borchelt, 1996, Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo, Neuron, 17, 1005, 10.1016/S0896-6273(00)80230-5 · DOI · Paper page
  39. Borlongan, 1997, 3-Nitropropionic acid animal model and Huntington's disease, Neurosci Biobehav Rev, 21, 289, 10.1016/S0149-7634(96)00027-9 · DOI
  40. Braak, 1996, Development of Alzheimer-related neurofibrillary changes in the neocortex inversely recapitulates cortical myelogenesis, Acta Neuropathol, 92, 197, 10.1007/s004010050508 · DOI · Paper page
  41. Bradford, 2009, Expression of mutant huntingtin in mouse brain astrocytes causes age-dependent neurological symptoms, Proc Natl Acad Sci USA, 106, 22480, 10.1073/pnas.0911503106 · DOI
  42. Bradford, 2010, Mutant huntingtin in glial cells exacerbates neurological symptoms of Huntington disease mice, J Biol Chem, 285, 10653, 10.1074/jbc.M109.083287 · DOI
  43. Brion, 1999, Transgenic expression of the shortest human tau affects its compartmentalization and its phosphorylation as in the pretangle stage of Alzheimer's disease, Am J Pathol, 154, 255, 10.1016/S0002-9440(10)65272-8 · DOI
  44. Broe, 2004, Astrocytic degeneration relates to the severity of disease in frontotemporal dementia, Brain, 127, 2214, 10.1093/brain/awh250 · DOI · Paper page
  45. Brouillet, 2005, 3-Nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease, J Neurochem, 95, 1521, 10.1111/j.1471-4159.2005.03515.x · DOI
  46. Brunello, 2009, Presenilin-2 dampens intracellular Ca2+ stores by increasing Ca2+ leakage and reducing Ca2+ uptake, J Cell Mol Med, 13, 3358, 10.1111/j.1582-4934.2009.00755.x · DOI
  47. Cannon, 2013, Expression of human E46K-mutated α-synuclein in BAC-transgenic rats replicates early-stage Parkinson's disease features and enhances vulnerability to mitochondrial impairment, Exp Neurol, 240, 44, 10.1016/j.expneurol.2012.11.007 · DOI
  48. Cardona, 2006, Control of microglial neurotoxicity by the fractalkine receptor, Nat Neurosci, 9, 917, 10.1038/nn1715 · DOI · Paper page
  49. Carmona, 2018, The genetic landscape of Alzheimer disease, Handb Clin Neurol, 148, 395, 10.1016/B978-0-444-64076-5.00026-0 · DOI
  50. Casley, 2009, Up-regulation of astrocyte metabotropic glutamate receptor 5 by amyloid-β peptide, Brain Res, 1260, 65, 10.1016/j.brainres.2008.12.082 · DOI
  51. Cerneckis, 2023, Pushing the boundaries of brain organoids to study Alzheimer's disease, Trends Mol Med, 29, 659, 10.1016/j.molmed.2023.05.007 · DOI
  52. Chandran, 2008, Progressive behavioral deficits in DJ-1-deficient mice are associated with normal nigrostriatal function, Neurobiol Dis, 29, 505, 10.1016/j.nbd.2007.11.011 · DOI
  53. Chatila, 2023, RNA- and ATAC-sequencing reveals a unique CD83+ microglial population focally depleted in Parkinson's disease, bioRxiv
  54. Chatterjee, 2021, Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer's disease, Transl Psychiatry, 11, 27, 10.1038/s41398-020-01137-1 · DOI · Paper page
  55. Chen, 2005, Age-dependent motor deficits and dopaminergic dysfunction in DJ-1 null mice, J Biol Chem, 280, 21418, 10.1074/jbc.M413955200 · DOI
  56. Chen, 2012, (G2019S) LRRK2 activates MKK4-JNK pathway and causes degeneration of SN dopaminergic neurons in a transgenic mouse model of PD, Cell Death Differ, 19, 1623, 10.1038/cdd.2012.42 · DOI
  57. Cheng, 2013, Significantly differential diffusion of neuropathological aggregates in the brain of transgenic mice carrying N-terminal mutant huntingtin fused with green fluorescent protein, Brain Struct Funct, 218, 283, 10.1007/s00429-012-0401-x · DOI
  58. Chia, 2020, Historical perspective: models of Parkinson's disease, Int J Mol Sci, 21, 2464, 10.3390/ijms21072464 · DOI
  59. Ciarmiello, 2006, Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington's disease, J Nucl Med, 47, 215
  60. Cicognola, 2021, Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment, Alzheimers Res Ther, 13, 68, 10.1186/s13195-021-00804-9 · DOI
  61. Clark, 2015, Alterations in synaptic plasticity coincide with deficits in spatial working memory in presymptomatic 3xTg-AD mice, Neurobiol Learn Mem, 125, 152, 10.1016/j.nlm.2015.09.003 · DOI
  62. Costa, 2010, Mitochondrial fission and cristae disruption increase the response of cell models of Huntington's disease to apoptotic stimuli, EMBO Mol Med, 2, 490, 10.1002/emmm.201000102 · DOI
  63. Crabtree, 2012, Genetically engineered mouse models of Parkinson's disease, Brain Res Bull, 88, 13, 10.1016/j.brainresbull.2011.07.019 · DOI
  64. Cummings, 2018, Lessons learned from Alzheimer disease: clinical trials with negative outcomes, Clin Transl Sci, 11, 147, 10.1111/cts.12491 · DOI · Paper page
  65. Czech, 1997, Proteolytical processing of mutated human amyloid precursor protein in transgenic mice, Brain Res Mol Brain Res, 47, 108, 10.1016/S0169-328X(97)00039-9 · DOI
  66. Daher, 2012, Neurodegenerative phenotypes in an A53T α-synuclein transgenic mouse model are independent of LRRK2, Hum Mol Genet, 21, 2420, 10.1093/hmg/dds057 · DOI
  67. Damiano, 2010, Mitochondria in Huntington's disease, Biochim Biophys Acta, 1802, 52, 10.1016/j.bbadis.2009.07.012 · DOI
  68. Day, 2021, The genetics of Parkinson's disease and implications for clinical practice, Genes (Basel), 12, 1006, 10.3390/genes12071006 · DOI
  69. de Rus Jacquet, 2023, The contribution of inflammatory astrocytes to BBB impairments in a brain-chip model of Parkinson's disease, Nat Commun, 14, 3651, 10.1038/s41467-023-39038-8 · DOI
  70. de Schipper, 2019, Age- and disease-related cerebral white matter changes in patients with Parkinson's disease, Neurobiol Aging, 80, 203, 10.1016/j.neurobiolaging.2019.05.004 · DOI
  71. De Strooper, 2016, The cellular phase of Alzheimer's disease, Cell, 164, 603, 10.1016/j.cell.2015.12.056 · DOI · Paper page
  72. Dematteis, 2020, Proteomic analysis links alterations of bioenergetics, mitochondria-ER interactions and proteostasis in hippocampal astrocytes from 3xTg-AD mice, Cell Death Dis, 11, 645, 10.1038/s41419-020-02911-1 · DOI
  73. Dexter, 1992, Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal ganglia. The Royal Kings and Queens Parkinson's Disease Research Group, Ann Neurol, 32, S94, 10.1002/ana.410320716 · DOI
  74. Dues, 2020, LRRK2 and protein aggregation in Parkinson's disease: insights from animal models, Front Neurosci, 14, 719, 10.3389/fnins.2020.00719 · DOI
  75. Duff, 1996, Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1, Nature, 383, 710, 10.1038/383710a0 · DOI
  76. Duff, 2000, Characterization of pathology in transgenic mice over-expressing human genomic and cDNA tau transgenes, Neurobiol Dis, 7, 87, 10.1006/nbdi.1999.0279 · DOI · Paper page
  77. El Tayara, 2010, Detection of vascular alterations by in vivo magnetic resonance angiography and histology in APP/PS1 mouse model of Alzheimer's disease, MAGMA, 23, 53, 10.1007/s10334-009-0194-y · DOI
  78. Faideau, 2010, In vivo expression of polyglutamine-expanded huntingtin by mouse striatal astrocytes impairs glutamate transport: a correlation with Huntington's disease subjects, Hum Mol Genet, 19, 3053, 10.1093/hmg/ddq212 · DOI
  79. Fajardo-Serrano, 2021, Adeno-associated viral vectors as versatile tools for Parkinson's research, both for disease modeling purposes and for therapeutic uses, Int J Mol Sci, 22, 6389, 10.3390/ijms22126389 · DOI · Paper page
  80. Fan, 2019, Mouse induced pluripotent stem cells-derived Alzheimer's disease cerebral organoid culture and neural differentiation disorders, Neurosci Lett, 711, 10.1016/j.neulet.2019.134433 · DOI
  81. Fernandez-Alvarez, 2022, Linking plasma amyloid beta and neurofilament light chain to intracortical myelin content in cognitively normal older adults, Front Aging Neurosci, 14, 10.3389/fnagi.2022.896848 · DOI
  82. Fernandez-Alvarez, 2023, Cortical amyloid-beta burden is associated with changes in intracortical myelin in cognitively normal older adults, Transl Psychiatry, 13, 115, 10.1038/s41398-023-02420-7 · DOI
  83. Ferrer, 2018, Oligodendrogliopathy in neurodegenerative diseases with abnormal protein aggregates: the forgotten partner, Prog Neurobiol, 169, 24, 10.1016/j.pneurobio.2018.07.004 · DOI
  84. Fleming, 2005, Genetic mouse models of parkinsonism: strengths and limitations, NeuroRx, 2, 495, 10.1602/neurorx.2.3.495 · DOI
  85. Flood, 2002, FAD mutant PS-1 gene-targeted mice: increased a beta 42 and a beta deposition without APP overproduction, Neurobiol Aging, 23, 335, 10.1016/S0197-4580(01)00330-X · DOI · Paper page
  86. Franciosi, 2012, Age-dependent neurovascular abnormalities and altered microglial morphology in the YAC128 mouse model of Huntington disease, Neurobiol Dis, 45, 438, 10.1016/j.nbd.2011.09.003 · DOI
  87. Fu, 2022, Adaptive structural changes in the motor cortex and white matter in Parkinson's disease, Acta Neuropathol, 144, 861, 10.1007/s00401-022-02488-3 · DOI
  88. Galla, 2020, Intracellular calcium dysregulation by the Alzheimer's disease-linked protein presenilin 2, Int J Mol Sci, 21, E770, 10.3390/ijms21030770 · DOI
  89. Games, 1995, Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein, Nature, 373, 523, 10.1038/373523a0 · DOI · Paper page
  90. Gargiulo, 2018, Up-regulation of COX-2 and mPGES-1 by 27-hydroxycholesterol and 4-hydroxynonenal: a crucial role in atherosclerotic plaque instability, Free Radic Biol Med, 129, 354, 10.1016/j.freeradbiomed.2018.09.046 · DOI
  91. Gil, 2008, Mechanisms of neurodegeneration in Huntington's disease, Eur J Neurosci, 27, 2803, 10.1111/j.1460-9568.2008.06310.x · DOI
  92. Giralt, 2010, BDNF regulation under GFAP promoter provides engineered astrocytes as a new approach for long-term protection in Huntington's disease, Gene Ther, 17, 1294, 10.1038/gt.2010.71 · DOI
  93. Gispert, 2003, Transgenic mice expressing mutant A53T human alpha-synuclein show neuronal dysfunction in the absence of aggregate formation, Mol Cell Neurosci, 24, 419, 10.1016/S1044-7431(03)00198-2 · DOI
  94. Gispert, 2009, Parkinson phenotype in aged PINK1-deficient mice is accompanied by progressive mitochondrial dysfunction in absence of neurodegeneration, PLoS One, 4, 10.1371/journal.pone.0005777 · DOI
  95. Goldberg, 2005, Nigrostriatal dopaminergic deficits and hypokinesia caused by inactivation of the familial Parkinsonism-linked gene DJ-1, Neuron, 45, 489, 10.1016/j.neuron.2005.01.041 · DOI
  96. Gong, 2023, Immortalized Alzheimer's disease astrocytes: characterization of their proteolytic systems, Mol Neurobiol, 10.1007/s12035-023-03231-z · DOI
  97. Götz, 1995, Somatodendritic localization and hyperphosphorylation of tau protein in transgenic mice expressing the longest human brain tau isoform, EMBO J, 14, 1304, 10.1002/j.1460-2075.1995.tb07116.x · DOI
  98. Götz, 2019, Molecular pathogenesis of the tauopathies, Annu Rev Pathol, 14, 239, 10.1146/annurev-pathmechdis-012418-012936 · DOI · Paper page
  99. Grant, 2015, Evidence for early and progressive ultrasonic vocalization and oromotor deficits in a PINK1 gene knockout rat model of Parkinson's disease, J Neurosci Res, 93, 1713, 10.1002/jnr.23625 · DOI
  100. Gray, 2019, Astrocytes in Huntington's disease, Adv Exp Med Biol, 1175, 355, 10.1007/978-981-13-9913-8_14 · DOI
  101. Gray, 2008, Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice, J Neurosci, 28, 6182, 10.1523/JNEUROSCI.0857-08.2008 · DOI
  102. Graybeal, 2015, Human ApoE ɛ4 alters circadian rhythm activity, IL-1β, and GFAP in CRND8 mice, J Alzheimers Dis, 43, 823, 10.3233/JAD-132009 · DOI
  103. Grigoletto, 2017, Higher levels of myelin phospholipids in brains of neuronal α-Synuclein transgenic mice precede myelin loss, Acta Neuropathol Commun, 5, 37, 10.1186/s40478-017-0439-3 · DOI
  104. Grolla, 2013, Amyloid-β and Alzheimer's disease type pathology differentially affects the calcium signalling toolkit in astrocytes from different brain regions, Cell Death Dis, 4, 10.1038/cddis.2013.145 · DOI
  105. Guillemaud, 2020, Complex roles for reactive astrocytes in the triple transgenic mouse model of Alzheimer disease, Neurobiol Aging, 90, 135, 10.1016/j.neurobiolaging.2020.02.010 · DOI
  106. Guo, 1999, Increased vulnerability of hippocampal neurons to excitotoxic necrosis in presenilin-1 mutant knock-in mice, Nat Med, 5, 101, 10.1038/4789 · DOI · Paper page
  107. Guttikonda, 2021, Fully defined human pluripotent stem cell-derived microglia and tri-culture system model C3 production in Alzheimer's disease, Nat Neurosci, 24, 343, 10.1038/s41593-020-00796-z · DOI
  108. Hamadjida, 2019, Classic animal models of Parkinson's disease: a historical perspective, Behav Pharmacol, 30, 291, 10.1097/FBP.0000000000000441 · DOI
  109. Hamza, 2010, Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease, Nat Genet, 42, 781, 10.1038/ng.642 · DOI
  110. Hansen, 2018, Microglia in Alzheimer's disease, J Cell Biol, 217, 459, 10.1083/jcb.201709069 · DOI · Paper page
  111. Harrison, 1998, Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia, Proc Natl Acad Sci USA, 95, 10896, 10.1073/pnas.95.18.10896 · DOI · Paper page
  112. Hashimoto, 2019, Tau binding protein CAPON induces tau aggregation and neurodegeneration, Nat Commun, 10, 2394, 10.1038/s41467-019-10278-x · DOI · Paper page
  113. Hattori, 2003, Distribution of astrocytic plaques in the corticobasal degeneration brain and comparison with tuft-shaped astrocytes in the progressive supranuclear palsy brain, Acta Neuropathol, 106, 143, 10.1007/s00401-003-0711-4 · DOI
  114. Hauw, 1990, Constant neurofibrillary changes in the neocortex in progressive supranuclear palsy. Basic differences with Alzheimer's disease and aging, Neurosci Lett, 119, 182, 10.1016/0304-3940(90)90829-X · DOI
  115. Heiland, 2019, Defined astrocytic expression of human amyloid precursor protein in Tg2576 mouse brain, Glia, 67, 393, 10.1002/glia.23550 · DOI
  116. Heng, 2010, Early autophagic response in a novel knock-in model of Huntington disease, Hum Mol Genet, 19, 3702, 10.1093/hmg/ddq285 · DOI
  117. Hodgson, 1999, A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration, Neuron, 23, 181, 10.1016/S0896-6273(00)80764-3 · DOI
  118. Holcomb, 1998, Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes, Nat Med, 4, 97, 10.1038/nm0198-097 · DOI · Paper page
  119. Hong, 2016, Mutant huntingtin impairs BDNF release from astrocytes by disrupting conversion of Rab3a-GTP into Rab3a-GDP, J Neurosci, 36, 8790, 10.1523/JNEUROSCI.0168-16.2016 · DOI
  120. Hsiao, 1996, Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice, Science, 274, 99, 10.1126/science.274.5284.99 · DOI · Paper page
  121. Huang, 2022, Chimeric cerebral organoids reveal the essentials of neuronal and astrocytic APOE4 for Alzheimer's tau pathology, Sig Transduct Target Ther, 7, 1, 10.1038/s41392-022-01006-x · DOI · Paper page
  122. Ihara, 2010, Quantification of myelin loss in frontal lobe white matter in vascular dementia, Alzheimer's disease, and dementia with Lewy bodies, Acta Neuropathol, 119, 579, 10.1007/s00401-009-0635-8 · DOI
  123. Irizarry, 1997, Abeta deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse, J Neurosci, 17, 7053, 10.1523/JNEUROSCI.17-18-07053.1997 · DOI · Paper page
  124. Ishihara, 1999, Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform, Neuron, 24, 751, 10.1016/S0896-6273(00)81127-7 · DOI · Paper page
  125. Jansen, 2017, Frequency of nuclear mutant huntingtin inclusion formation in neurons and glia is cell-type-specific, Glia, 65, 50, 10.1002/glia.23050 · DOI
  126. Janus, 2000, A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease, Nature, 408, 979, 10.1038/35050110 · DOI · Paper page
  127. Jones, 2017, Aberrant iPSC-derived human astrocytes in Alzheimer's disease, Cell Death Dis, 8, 10.1038/cddis.2017.89 · DOI · Paper page
  128. Jun, 2022, Protein phosphatase 2A and complement component 4 are linked to the protective effect of APOE ɛ2 for Alzheimer's disease, Alzheimers Dement, 10.1002/alz.12607 · DOI
  129. Kanemaru, 2013, Calcium-dependent N-cadherin up-regulation mediates reactive astrogliosis and neuroprotection after brain injury, Proc Natl Acad Sci USA, 110, 11612, 10.1073/pnas.1300378110 · DOI
  130. Katsurabayashi, 2016, Overexpression of Swedish mutant APP in aged astrocytes attenuates excitatory synaptic transmission, Physiol Rep, 4, 10.14814/phy2.12665 · DOI
  131. Kavroulakis, 2018, Myelin content changes in probable Alzheimer's disease and mild cognitive impairment: associations with age and severity of neuropsychiatric impairment, J Magn Reson Imaging, 47, 1359, 10.1002/jmri.25849 · DOI
  132. Kaye, 2021, Huntington's disease mouse models: unraveling the pathology caused by CAG repeat expansion, Fac Rev, 10, 77, 10.12703/r/10-77 · DOI
  133. Ke, 2021, Comprehensive perspectives on experimental models for Parkinson's disease, Aging Dis, 12, 223, 10.14336/AD.2020.0331 · DOI
  134. Kersaitis, 2004, Regional and cellular pathology in frontotemporal dementia: relationship to stage of disease in cases with and without Pick bodies, Acta Neuropathol, 108, 515, 10.1007/s00401-004-0917-0 · DOI
  135. Khakh, 2019, Astrocyte-neuron interactions in the striatum: insights on identity, form, and function, Trends Neurosci, 42, 617, 10.1016/j.tins.2019.06.003 · DOI
  136. Khakh, 2023, Astrocytic contributions to Huntington's disease pathophysiology, Ann N Y Acad Sci, 1522, 42, 10.1111/nyas.14977 · DOI
  137. Khiroug, 2021, Coming full circle: in vivo Veritas, or expanding the neuroscience frontier, Cell Calcium, 98, 10.1016/j.ceca.2021.102452 · DOI
  138. Kitada, 2009, Absence of nigral degeneration in aged parkin/DJ-1/PINK1 triple knockout mice, J Neurochem, 111, 696, 10.1111/j.1471-4159.2009.06350.x · DOI
  139. Kohutnicka, 1998, Microglial and astrocytic involvement in a murine model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), Immunopharmacology, 39, 167, 10.1016/S0162-3109(98)00022-8 · DOI
  140. Konttinen, 2019, PPARβ/δ-agonist GW0742 ameliorates dysfunction in fatty acid oxidation in PSEN1ΔE9 astrocytes, Glia, 67, 146, 10.1002/glia.23534 · DOI
  141. Koprich, 2016, Towards a non-human primate model of alpha-synucleinopathy for development of therapeutics for Parkinson's disease: optimization of AAV1/2 delivery parameters to drive sustained expression of alpha synuclein and dopaminergic degeneration in macaque, PLoS One, 11, 10.1371/journal.pone.0167235 · DOI
  142. Kosior, 2018, Murine models of Huntington's disease for evaluating therapeutics, Methods Mol Biol, 1780, 179, 10.1007/978-1-4939-7825-0_10 · DOI
  143. Kotliarova, 2005, Decreased expression of hypothalamic neuropeptides in Huntington disease transgenic mice with expanded polyglutamine-EGFP fluorescent aggregates, J Neurochem, 93, 641, 10.1111/j.1471-4159.2005.03035.x · DOI
  144. Kotredes, 2021, Uncovering disease mechanisms in a novel mouse model expressing humanized APOEɛ4 and Trem2*R47H, Front Aging Neurosci, 13, 10.3389/fnagi.2021.735524 · DOI · Paper page
  145. Kotredes, 2021, LOAD2: a late-onset Alzheimer's disease mouse model expressing APOEɛ4, Trem2*R47H, and humanized amyloid-beta, Alzheimers Dement, 17, 10.1002/alz.056017 · DOI
  146. Kovacs, 2020, Astroglia and tau: new perspectives, Front Aging Neurosci, 12, 96, 10.3389/fnagi.2020.00096 · DOI · Paper page
  147. Kovacs, 2013, Neuropathology of the hippocampus in FTLD-Tau with Pick bodies: a study of the BrainNet Europe Consortium, Neuropathol Appl Neurobiol, 39, 166, 10.1111/j.1365-2990.2012.01272.x · DOI
  148. Kraft, 2012, Activated microglia proliferate at neurites of mutant huntingtin-expressing neurons, Neurobiol Aging, 33, 10.1016/j.neurobiolaging.2011.02.015 · DOI
  149. Kuchibhotla, 2009, Synchronous hyperactivity and intercellular calcium waves in astrocytes in Alzheimer mice, Science, 323, 1211, 10.1126/science.1169096 · DOI · Paper page
  150. Kuijlaars, 2016, Sustained synchronized neuronal network activity in a human astrocyte co-culture system, Sci Rep, 6, 36529, 10.1038/srep36529 · DOI
  151. Larson, 1999, Alterations in synaptic transmission and long-term potentiation in hippocampal slices from young and aged PDAPP mice, Brain Res, 840, 23, 10.1016/S0006-8993(99)01698-4 · DOI
  152. Lee, 2012, Tau and tauopathies, Prog Mol Biol Transl Sci, 107, 263, 10.1016/B978-0-12-385883-2.00004-7 · DOI
  153. Lee, 1997, Hyperaccumulation of FAD-linked presenilin 1 variants in vivo, Nat Med, 3, 756, 10.1038/nm0797-756 · DOI
  154. Lee, M.K., Stirling, W., Xu, Y., Xu, X., Qui, D., Mandir, A.S., Dawson, T.M., Copeland, N.G., Jenkins, N.A., Price, D.L., 2002. Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 --> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proc Natl Acad Sci USA 99, 8968–8973. doi:https://doi.org/10.1073/pnas.132197599 · DOI · Paper page
  155. Lee, 2013, Enhanced Ca(2+)-dependent glutamate release from astrocytes of the BACHD Huntington's disease mouse model, Neurobiol Dis, 58, 192, 10.1016/j.nbd.2013.06.002 · DOI
  156. Lee, 2017, 3D brain organoids derived from pluripotent stem cells: promising experimental models for brain development and neurodegenerative disorders, J Biomed Sci, 24, 59, 10.1186/s12929-017-0362-8 · DOI
  157. Lee, 2017, Network degeneration and dysfunction in presymptomatic C9ORF72 expansion carriers, Neuroimage Clin, 14, 286, 10.1016/j.nicl.2016.12.006 · DOI · Paper page
  158. Lee, 2019, Parkinson's disease-associated LRRK2-G2019S mutant acts through regulation of SERCA activity to control ER stress in astrocytes, Acta Neuropathol Commun, 7, 68, 10.1186/s40478-019-0716-4 · DOI
  159. Levine, 1999, Enhanced sensitivity to N-methyl-D-aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease, J Neurosci Res, 58, 515, 10.1002/(SICI)1097-4547(19991115)58:4<515::AID-JNR5>3.0.CO;2-F · DOI
  160. Lewcock, 2020, Emerging microglia biology defines novel therapeutic approaches for Alzheimer's disease, Neuron, 108, 801, 10.1016/j.neuron.2020.09.029 · DOI · Paper page
  161. Lewis, 2000, Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein, Nat Genet, 25, 402, 10.1038/78078 · DOI · Paper page
  162. Lewis, 2001, Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP, Science, 293, 1487, 10.1126/science.1058189 · DOI · Paper page
  163. Li, 2009, Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease, Nat Neurosci, 12, 826, 10.1038/nn.2349 · DOI
  164. Lia, 2023, Rescue of astrocyte activity by the calcium sensor STIM1 restores long-term synaptic plasticity in female mice modelling Alzheimer's disease, Nat Commun, 14, 1590, 10.1038/s41467-023-37240-2 · DOI
  165. Lim, 2001, FTDP-17 mutations in tau transgenic mice provoke lysosomal abnormalities and tau filaments in forebrain, Mol Cell Neurosci, 18, 702, 10.1006/mcne.2001.1051 · DOI
  166. Lim, 2008, Calcium homeostasis and mitochondrial dysfunction in striatal neurons of Huntington disease, J Biol Chem, 283, 5780, 10.1074/jbc.M704704200 · DOI
  167. Lim, 2014, Glial calcium signalling in Alzheimer's disease, Rev Physiol Biochem Pharmacol, 167, 45, 10.1007/112_2014_19 · DOI
  168. Lim, 2016, Calcium signalling toolkits in astrocytes and spatio-temporal progression of Alzheimer's disease, Curr Alzheimer Res, 13, 359, 10.2174/1567205013666151116130104 · DOI
  169. Lim, 2021, Calcium signaling in neuroglia, Int Rev Cell Mol Biol, 362, 1, 10.1016/bs.ircmb.2021.01.003 · DOI
  170. Lim, 2023, The endoplasmic reticulum stress and unfolded protein response in Alzheimer's disease: a calcium dyshomeostasis perspective, Ageing Res Rev, 87, 10.1016/j.arr.2023.101914 · DOI
  171. Lin, 2001, Neurological abnormalities in a knock-in mouse model of Huntington's disease, Hum Mol Genet, 10, 137, 10.1093/hmg/10.2.137 · DOI
  172. Lin, 2009, Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson’s-disease-related mutant alpha-synuclein, Neuron, 64, 807, 10.1016/j.neuron.2009.11.006 · DOI
  173. Lines, 2022, Astrocyte-neuronal network interplay is disrupted in Alzheimer's disease mice, Glia, 70, 368, 10.1002/glia.24112 · DOI
  174. Lippi, 2018, A novel hAPP/htau mouse model of Alzheimer's disease: inclusion of APP with tau exacerbates behavioral deficits and zinc administration heightens tangle pathology, Front Aging Neurosci, 10, 382, 10.3389/fnagi.2018.00382 · DOI
  175. Lord, 2006, The Arctic Alzheimer mutation facilitates early intraneuronal Abeta aggregation and senile plaque formation in transgenic mice, Neurobiol Aging, 27, 67, 10.1016/j.neurobiolaging.2004.12.007 · DOI · Paper page
  176. Luczynski, 2019, Coexistence of multiple sclerosis and Alzheimer's disease: a review, Mult Scler Relat Disord, 27, 232, 10.1016/j.msard.2018.10.109 · DOI
  177. Ludolph, 1991, 3-Nitropropionic acid-exogenous animal neurotoxin and possible human striatal toxin, Can J Neurol Sci, 18, 492, 10.1017/S0317167100032212 · DOI
  178. Malthankar-Phatak, 2012, Amyloid deposition and advanced age fails to induce Alzheimer's type progression in a double knock-in mouse model, Aging Dis, 3, 141
  179. Mangiarini, 1996, Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice, Cell, 87, 493, 10.1016/S0092-8674(00)81369-0 · DOI · Paper page
  180. Masliah, 2000, Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders, Science, 287, 1265, 10.1126/science.287.5456.1265 · DOI
  181. Masuda, 2016, Cognitive deficits in single App knock-in mouse models, Neurobiol Learn Mem, 135, 73, 10.1016/j.nlm.2016.07.001 · DOI · Paper page
  182. Mateos, 2011, Upregulation of brain renin angiotensin system by 27-hydroxycholesterol in Alzheimer's disease, J Alzheimers Dis, 24, 669, 10.3233/JAD-2011-101512 · DOI
  183. Mehla, 2019, Age-dependent behavioral and biochemical characterization of single APP knock-in mouse (APPNL-G-F/NL-G-F) model of Alzheimer's disease, Neurobiol Aging, 75, 25, 10.1016/j.neurobiolaging.2018.10.026 · DOI · Paper page
  184. Mehta, 2017, Why do trials for Alzheimer's disease drugs keep failing? A discontinued drug perspective for 2010-2015, Expert Opin Investig Drugs, 26, 735, 10.1080/13543784.2017.1323868 · DOI
  185. Menalled, 2003, Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington's disease with 140 CAG repeats, J Comp Neurol, 465, 11, 10.1002/cne.10776 · DOI
  186. Menalled, 2012, Comprehensive behavioral and molecular characterization of a new knock-in mouse model of Huntington's disease: zQ175, PLoS One, 7, 10.1371/journal.pone.0049838 · DOI
  187. Mikhail, 2015, Lack of exacerbation of neurodegeneration in a double transgenic mouse model of mutant LRRK2 and tau, Hum Mol Genet, 24, 3545, 10.1093/hmg/ddv105 · DOI
  188. Moechars, 1999, Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain, J Biol Chem, 274, 6483, 10.1074/jbc.274.10.6483 · DOI · Paper page
  189. Moser, 1995, Developmental expression of the prion protein gene in glial cells, Neuron, 14, 509, 10.1016/0896-6273(95)90307-0 · DOI
  190. Mucke, 2000, High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation, J Neurosci, 20, 4050, 10.1523/JNEUROSCI.20-11-04050.2000 · DOI · Paper page
  191. Nam, 2023, Visualizing reactive astrocyte-neuron interaction in Alzheimer's disease using 11C-acetate and 18F-FDG, Brain, 146, 2957, 10.1093/brain/awad037 · DOI
  192. Nguyen, 2018, G2019S LRRK2 enhances the neuronal transmission of tau in the mouse brain, Hum Mol Genet, 27, 120, 10.1093/hmg/ddx389 · DOI
  193. Nudelman, 2022, TREM2 variants in Parkinson's disease: results from the Parkinson's Progression Markers Initiative (PPMI) Study, Alzheimers Dement, 18, 10.1002/alz.062316 · DOI
  194. Octeau, 2018, An optical neuron-astrocyte proximity assay at synaptic distance scales, Neuron, 98, 49, 10.1016/j.neuron.2018.03.003 · DOI
  195. Oddo, 2003, Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction, Neuron, 39, 409, 10.1016/S0896-6273(03)00434-3 · DOI · Paper page
  196. Olabarria, 2010, Concomitant astroglial atrophy and astrogliosis in a triple transgenic animal model of Alzheimer's disease, Glia, 58, 831, 10.1002/glia.20967 · DOI · Paper page
  197. Orre, 2014, Acute isolation and transcriptome characterization of cortical astrocytes and microglia from young and aged mice, Neurobiol Aging, 35, 1, 10.1016/j.neurobiolaging.2013.07.008 · DOI
  198. Palacino, 2004, Mitochondrial dysfunction and oxidative damage in parkin-deficient mice, J Biol Chem, 279, 18614, 10.1074/jbc.M401135200 · DOI · Paper page
  199. Paulson, 2008, Amyloid plaque and neurofibrillary tangle pathology in a regulatable mouse model of Alzheimer's disease, Am J Pathol, 173, 762, 10.2353/ajpath.2008.080175 · DOI
  200. Pereira, 2021, Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer's disease, Brain, 144, 3505, 10.1093/brain/awab223 · DOI · Paper page

200 of 331 shown

Cited by

Sorted by citations

Metadata

Authors
Lim, D., Matute, C., Cavaliere, F., & Verkhratsky, A.
Venue
Handbook of Clinical Neurology
Publisher
Elsevier
Published
2025
Pages
9-44
ISSN
0072-9752
DOI
10.1016/b978-0-443-19102-2.00012-0
Cited by
8
References
63
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review